Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
While Eli Lilly and Company ( NYSE:LLY ) shareholders are probably generally happy, the stock hasn't had particularly... The U.S. Food and Drug Administration (FDA) recently approved Zepbound ...
FierceBiotech4h
Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
FiercePharma11d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
The company is also testing tirzepatide in heart failure ... said in the report. “Now with Zepbound, the revolution ...
Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...